Morepen Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Morepen Laboratories has a total shareholder equity of ₹11.1B and total debt of ₹334.9M, which brings its debt-to-equity ratio to 3%. Its total assets and total liabilities are ₹15.6B and ₹4.5B respectively. Morepen Laboratories's EBIT is ₹1.8B making its interest coverage ratio 65.5. It has cash and short-term investments of ₹1.9B.
Key information
3.0%
Debt to equity ratio
₹334.95m
Debt
| Interest coverage ratio | 65.5x |
| Cash | ₹1.86b |
| Equity | ₹11.10b |
| Total liabilities | ₹4.52b |
| Total assets | ₹15.62b |
Recent financial health updates
Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13
Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
Recent updates
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump
Aug 20Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)
Aug 09Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified
Jul 05Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing
Apr 23Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16Financial Position Analysis
Short Term Liabilities: MOREPENLAB's short term assets (₹10.9B) exceed its short term liabilities (₹4.1B).
Long Term Liabilities: MOREPENLAB's short term assets (₹10.9B) exceed its long term liabilities (₹453.2M).
Debt to Equity History and Analysis
Debt Level: MOREPENLAB has more cash than its total debt.
Reducing Debt: MOREPENLAB's debt to equity ratio has reduced from 64.2% to 3% over the past 5 years.
Debt Coverage: MOREPENLAB's debt is well covered by operating cash flow (144.2%).
Interest Coverage: MOREPENLAB's interest payments on its debt are well covered by EBIT (65.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:49 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Morepen Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vijay Madunala | FirstCall Research |